Citeline Podcasts
1,366 episodes - English - Latest episode: 2 days ago - ★★★★★ - 24 ratingsCiteline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Scrip Lifetime Achievement Award 2023: Jeremy Levin’s Acceptance Speech
November 22, 2023 17:45 - 9 minutes - 17.1 MBIn accepting Scrip’s Lifetime Achievement Award, Ovid Therapeutics’ CEO called on pharma to show responsible leadership and live up to its potential to do good for society.
China Biotech Podcast (Chinese language) - November 2023
November 21, 2023 14:20 - 32 minutes - 14.3 MBBrian Yang and Dexter Yan discuss the FDA approval of Chinese PD-1, Sanofi BioMap AI deal, Third quarter earnings and Biden-Xi Summit and US-China regulatory dialogue.
Discussing The Potentials Of And Challenges For Digital Therapeutics
November 21, 2023 09:18 - 31 minutes - 29.2 MBIn this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythyms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.
Digital Health Roundup: Black Friday Hits – Digital Twins, Biowearables, Robotics, Cardiology
November 21, 2023 03:27 - 13 minutes - 6.11 MBIn this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona. Medtech Insight articles addressing topics discussed in this episode: Can Digital Twin Tech...
Scrip’s Five Must-Know Things – 20 November 2023
November 20, 2023 09:02 - 14 minutes - 20.1 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever? https://scrip.citeline.com/SC149388/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: Janet Woodcock retiring, Accelerated Approval Reform, US FDA Meeting Recording Policy
November 17, 2023 18:59 - 43 minutes - 25.7 MBPink Sheet reporters and editors discuss US FDA Principal Deputy Commissioner Janet Woodcock’s legacy as her retirement approaches (:42), the stance of the FDA’s oncology division on confirming benefit after an accelerated approval (16:59), and why formal meetings between the agency and sponsors cannot be recorded (36:51). More On These Topics From The Pink Sheet With Woodcock’s Retirement, US FDA Loses A Renaissance Woman: https://pink.citeline.com/PS149368/With-Woodcocks-Retirement-US-FDA...
Syngene CEO On Sub-Dynamics As US Biotech Funding Finds New Normal, ADC Capabilities
November 17, 2023 11:32 - 56 minutes - 23.9 MBSyngene’s MD & CEO, Jonathan Hunt, in an interview with Scrip, dissects trends and opportunities in the CRDMO segment as US biotechs slow their burn rate amid a funding squeeze while other large and medium-sized biopharma firms seek to rebalance their supply chain. The Indian firm’s ability to add value in the development and manufacture of ADCs and also its partnership with Amgen are some of the other topics the ex-AstraZeneca executive discusses.
Scrip’s Five Must-Know Things – 13 November 2023
November 13, 2023 06:21 - 16 minutes - 22.5 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: US approval for Lilly’s obesity drug; a look at the future of the obesity market; BMS’s ADC deal; Roche’s MS plans; and one Chinese firm’s CAR-T plans. https://scrip.citeline.com/SC149349/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: FTC Orange Book Patent Challenges, Ad/Promo Due Diligence, US FDA Adcomm Decision Appeal
November 10, 2023 18:54 - 27 minutes - 16.6 MBPink Sheet reporter and editors discuss the FTC’s challenges of Orange Book patents (:35), DTC promotion practices as part of acquisition due diligence (12:39), and how Intarcia’s advisory committee decision appeal could play out (19:06). More On These Topics From The Pink Sheet In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap: https://pink.citeline.com/PS149316/In-Swift-Challenge-To-Orange-Book-Patent-Listings-Federal-Trade-Commission-Fi...
How OTC Companies Can Respond To Preventative Health Trends - With Simon Kucher & Partners
November 10, 2023 12:39 - 46 minutes - 107 MBIn this episode, HBW Insight speaks to Simon-Kucher & Partners about the latest trends in preventative consumer health. Partner Christian Rebholz and senior director Lorenzo Eandi explain the findings from the company’s recently published Better Health Report, which reached out to almost 3,000 consumers from across the world. We take a deeper dive into Brazil, where consumers are spending more on than average on preventative health, and Germany, where consumers are spending less but are turni...
Humira Biosimilar Landscape Podcast
November 08, 2023 12:42 - 23 minutes - 9.94 MBHumira Biosimilar Landscape Other platforms Apple Podcasts - https://podcasts.apple.com/us/podcast/pharma-intelligence-podcasts/id923189836 Google Podcasts - https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5zb3VuZGNsb3VkLmNvbS91c2Vycy9zb3VuZGNsb3VkOnVzZXJzOjEwNjU1NDkyOC9zb3VuZHMucnNz TuneIn - https://tunein.com/podcasts/Business--Economics-Podcasts/Pharma-Intelligence-Podcasts-p1140128/ Spotify Podcasts - https://open.spotify.com/show/3DTc3eIh4xI6pVOd6DdO67
일본 최대 바이오클러스터, 한국 바이오벤처들과 CGT 협업 추진 (Korean-language podcast)
November 07, 2023 00:51 - 3 minutes - 3.93 MB일본 최대 제약바이오 R&D 허브와 한국 바이오벤처들이 세포유전자치료제 분야의 협업을 활발히 추진하고 있다는 Scrip 기사를 요약한 내용입니다. https://scrip.citeline.com/SC149214/Japans-Largest-Biocluster-Korean-Ventures-To-Collaborate-For-Cell-And-Gene-Therapies
Scrip’s Five Must-Know Things – 6 November 2023
November 06, 2023 03:46 - 15 minutes - 19.7 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: CEOs on global tensions; Roche’s new Alzheimer's contender; Sanofi eyes external deals; investors’ reactions to clinical data; and Korean licensing pitfalls https://scrip.citeline.com/SC149308/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: CMS Listens On Price Negotiations, Elevidys Top-Line Trial Data, Gene Therapy Reg Changes
November 03, 2023 17:47 - 40 minutes - 26 MBPink Sheet reporters and editor discuss take-aways from the first Medicare price negotiation program public listening sessions (:35), next steps after Sarepta reported questionable top-line data for its Duchenne muscular dystrophy gene therapy Elevidys (14:45), and indications the FDA may adjust its regulatory approach to gene editing products (26:27). More On These Topics From The Pink Sheet Could Government Negotiated Prices Curtail Access? PBMs And Potential Perverse Incentives Dominate ...
【3分で解説 世界のファーマ】第14回 承認２カ月後に新薬発売へ、スイスの新制度 (Japanese-language podcast)
November 02, 2023 03:01 - 3 minutes - 3.65 MB世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら 「Swiss To Introduce Parallel HTA & Regulatory Submissions, More Transparent Decisions（邦題意訳：新たな制度を導入のスイス、医薬品審査の透明性確保へ）」 https://pink.citeline.com/PS149096/Swiss-To-Introduce-Parallel-HTA--Regulatory-Submissions-More-Transparent-Decisions 世界の薬事規制ニュースPink Sheet（ピンクシート）とは？ https://www.citeline.com/ja-jp/products-services/regulatory-and-compliance/pink-sheet
Podcast: Overcoming regulatory challenges in a complex clinical trial landscape
November 01, 2023 12:53 - 17 minutes - 8.54 MBListen in as Citeline sits down with a regulatory and compliance expert Mai Mishir, Senior Director, Global Regulatory Affairs from Advanced Clinical. Capture new insights into the present state of regulatory as advancements in technology, a shift to patient-centricity, and the globalization of clinical trials combine to change workflows and trial design. Plan your strategy now and develop new ways to master these complexities, with information from this free podcast.
Biotech CEO Podcast with William Wei Cao of Gracell Bio
November 01, 2023 07:34 - 52 minutes - 20.7 MBBrian Yang interviews Nasdaq-listed cell therapy developer Gracell Bio Founder and CEO William Wei Cao who discussed the plan to enter the US market through quicker turnaround, faster delivery, cost-effective and safety profile. He also discussed taking the Shanghai-based firm’s CD19 and BCMA-dual targeted therapy to the first-line treatment, allogenic CAR-T therapies, combinations, Chinese biotech going global and surviving in the current “capital winter” environment.
Biotech CEO Podcast with William Wei Cao of Gracell Bio
November 01, 2023 07:29 - 52 minutes - 20.7 MBBrian Yang interviews Nasdaq-listed cell therapy developer Gracell Bio Founder and CEO William Wei Cao who discussed the plan to enter the US market through quicker turnaround, faster delivery, cost-effective and safety profile. He also discussed taking the Shanghai-based firm’s CD19 and BCMA-dual targeted therapy to the first-line treatment, allogenic CAR-T therapies, combinations, Chinese biotech going global and surviving in the current “capital winter” environment.
China Biotech Podcast (Chinese language) - October 2023
October 31, 2023 04:19 - 27 minutes - 12.1 MBIn this Chinese-language podcast, Brian Yang and Dexter Yan discuss China biotech topics including the annual IND and NDA report from Center for Drug Evaluation, ESMO’s China data and Shanghai International Biotech Industry Week. https://scrip.citeline.com/SC149259/Chinese-Language-Podcast-ESMO-China-Data-Annual-CDE-Report-Shanghai-Biotech-Week
Scrip’s Five Must-Know Things – 30 October 2023
October 30, 2023 03:25 - 12 minutes - 17.2 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcutaneous Leqembi could open up access. https://scrip.citeline.com/SC149266/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: Off-Label Coms Guidance, Price Negotiations And Prescribing, Bertagnolli’s NIH Bid
October 27, 2023 16:23 - 24 minutes - 15 MBPink Sheet reporters and editors discuss new off-label use communications guidance (:35), how price negotiations could impact prescribing (9:49), and Monica Bertagnolli’s nomination for NIH director advancing (17:18). More On These Topics From The Pink Sheet Off-Label Guidance Creates ‘Safe Harbor’ For Dissemination of Certain Info To HCPs: https://pink.citeline.com/PS149058/Off-Label-Guidance-Creates-Safe-Harbor-For-Dissemination-of-Certain-Info-To-HCPs Underwater: Medicare Negotiated Pr...
AI In Behavioral Health Clinics
October 25, 2023 00:14 - 14 minutes - 7.14 MBIn this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with behavioral health experts on implementing AI solutions to help ease the administrative burden on clinicians as well as recent coverage from the LSX Congress USA and HLTH conferences. Reed Miller discusses findings of EY’s annual pulse of the medtech industry report and Hannah Daniel discusses FDA guidance on regulating AI/ML. Medtech Insight articles addressing topics discussed in this episode: ...
Over The Counter 24 Oct 2023: An Approach To MoCRA With Good Face Project’s Iva Teixeira
October 24, 2023 01:00 - 43 minutes - 19.9 MBOver The Counter 24 Oct 2023: An Approach To MoCRA With Good Face Project’s Iva Teixeira by Citeline
Scrip’s Five Must-Know Things – 23 October 2023
October 23, 2023 04:18 - 16 minutes - 22.8 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Daiichi’s huge ADC deal with Merck; mixed data for Rybrevant at ESMO; Pfizer girds for cost cuts; myeloma helps J&J’s Q3; and five key points for cell and gene Meeting on the Mesa. https://scrip.citeline.com/SC149230/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: BrainStorm Withdraws NurOwn, NIH Nominee On Drug Pricing, Gene Therapy Long-Term Follow-Up
October 20, 2023 18:28 - 31 minutes - 19.3 MBPink Sheet reporters and editor discuss BrainStorm’s next steps after withdrawing the NurOwn BLA (:38), NIH director nominee Monica Bertagnolli’s thoughts on drug affordability (8:13), and the US FDA’s effort to ensure long-term follow-up of gene therapy patients (19:41). More On These Topics From The Pink Sheet BrainStorm Eyes New Phase III Trial For NurOwn In Mild ALS Following BLA Withdrawal: https://pink.citeline.com/PS149035/BrainStorm-Eyes-New-Phase-III-Trial-For-NurOwn-In-Mild-ALS-Fo...
Medtech Insight: The Realities Of Real-World Evidence.
October 18, 2023 19:03 - 22 minutes - 9.91 MBn this special podcast, Medtech Insight managing editor Elizabeth Orr talks to consultant Steve Silverman about the FDA’s current position on real-world evidence and real-world data, as well as how manufacturers can best put the evidence types to use.
Q&A with Dr. Marc Sandberg: A Specialist in Endocrinology, Diabetes & Metabolism
October 18, 2023 14:14 - 7 minutes - 10.4 MBQ&A with Dr. Marc Sandberg: A Specialist in Endocrinology, Diabetes & Metabolism by Citeline
Centrient Delivers Innovation In Biotechnology
October 17, 2023 09:03 - 12 minutes - 7.29 MBListen as executives from Centrient Pharmaceuticals share insider perspectives on innovations in sustainable, efficient, clean manufacturing practices.
Q&A with Sleep Medicine Specialist Nathaniel Watson, MD
October 16, 2023 19:00 - 7 minutes - 10.4 MBQ&A with Sleep Medicine Specialist Nathaniel Watson, MD by Citeline
Scrip’s Five Must-Know Things – 16 October 2023
October 16, 2023 04:13 - 15 minutes - 19.2 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: BMS buys Mirati; slow Q3 for biopharma M&A; Roche on its neuroscience strategy; Alexion talks about AstraZeneca integration; and Gilead on trial diversity. https://scrip.citeline.com/SC149190/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: US FDA Suffers From Shutdown Threat, Alnylam’s CR Letter, ARPA-H Wants FDA Incentives
October 13, 2023 18:10 - 30 minutes - 18.7 MBPink Sheet reporters and editor discuss the problems that emerged for the US FDA from just the threat of a government shutdown (:38), take-aways on the FDA advisory committee process based on the complete response letter issued for Alnylam’s Onpattro (10:25), and incentives that the FDA could offer for ARPA-H projects that reach the application stage (20:16). More On These Topics From The Pink Sheet Shutdown Threat Forced US FDA To Cancel Some Travel: https://pink.citeline.com/PS149003/Shut...
Scrip’s Five Must-Know Things – 11 October 2023
October 11, 2023 06:16 - 14 minutes - 19.9 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Lilly’s radiopharmaceutical buy; strong third quarter for biotech financing; Novartis’s nephropathy results; US ICER runs cost analysis on first batch of drugs; and the outlook for US FTC oversight of biopharma M&A. https://scrip.citeline.com/SC149170/Quick-Listen-Scrips-Five-MustKnow-Things
아일랜드, 글로벌 제약사의 투자처로 각광 (Korean-language podcast)
October 09, 2023 06:42 - 3 minutes - 3.86 MB릴리, 다케다, 아스트라제네카에 이어 MSD, 아스텔라스도 아일랜드에 대규모 투자 동참 https://scrip.citeline.com/SC149047/Pharma-Cash-Keeps-Flowing-Into-Ireland
What’s Going On With Oral Phenylephrine In The US? With HBW’s Malcolm Spicer
October 06, 2023 15:57 - 42 minutes - 96.6 MBIn this episode, HBW Insight speaks to its own OTC expert, managing editor Malcom Spicer, about recent controversy in the US surrounding oral nasal decongestant active ingredient phenylephrine. Used widely and safely by US consumers for around a half century, the efficacy of oral phenylephrine has come under question following a 2015 citizen petition by University of Florida pharmaceutical researchers, which asked the FDA to remove the ingredient from the final OTC CCABA monograph. Only recen...
Medtech Connect Episode 10: Breaking Down The Transitional Coverage Of Emerging Technologies
October 04, 2023 21:35 - 24 minutes - 16.4 MBIn this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to Washington Analysis vice president and senior healthcare analyst John Leppard about the Center for Medicare and Medicaid’s Transitional Coverage Of Emerging Technologies pathway, or TCET. He breaks down the pathway and discusses its pros and cons, as well as potential next steps for the agency. We also explore the history of breakthrough device coverage as well as the challenges for coverage of digital health devices.
Scrip’s Five Must-Know Things – 3 October 2023
October 03, 2023 00:18 - 15 minutes - 20.3 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs. https://scrip.citeline.com/SC149131/Quick-Listen-Scrips-Five-MustKnow-Things
Scrip M&A Podcast: US FTC Review of Mergers and Acquisitions
October 02, 2023 16:04 - 37 minutes - 15.6 MBScrip writers Joseph Haas and Jessica Merrill discuss US FTC overview of biopharma mergers like Amgen/Horizon and Pfizer/Seagen with Leerink Partners' analyst Dan Lepanto and ZS Associates partner Cody Powers.
Drug Fix: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
September 29, 2023 14:38 - 32 minutes - 19.8 MBPink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug (:43), the impact of a government shutdown on the agency (10:00), and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations (22:58). More On These Topics From The Pink Sheet BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel: https://pink.citeline.com/PS148915/B...
Scrip’s Five Must-Know Things – 28 September 2023
September 28, 2023 02:39 - 15 minutes - 22 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2’s top-selling drugs. https://scrip.citeline.com/SC149111/Quick-Listen-Scrips-Five-MustKnow-Things
Disrupting the Consumer Health Industry, With Maxwellia’s Anna Maxwell
September 25, 2023 13:56 - 21 minutes - 49 MBIn this episode, HBW Insight catches up with UK switch specialists Maxwellia to find out what’s next for the company that gave to the UK one of the first OTC daily contraceptive pills. Now a disruptive consumer health player in its own right, the company is looking for investors to take it to the next level and help launch two new women’s health products in the pipeline for next year, CEO Anna Maxwell reveals in this exclusive interview.
Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart
September 25, 2023 09:47 - 30 minutes - 13.4 MBIndustry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.
Scrip’s Five Must-Know Things – 20 September 2023
September 20, 2023 03:49 - 15 minutes - 21 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s. https://scrip.citeline.com/SC149072/Quick-Listen-Scrips-Five-MustKnow-Things
Drug Fix: Regeneron’s COVID Monoclonal Deal, New FDA Advisor, Project Optimus In Cancer Combos
September 15, 2023 16:33 - 30 minutes - 18.5 MBPink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody (:34), US FDA Commissioner Robert Califf hiring a new senior advisor (12:10), and optimizing dosing in cancer combination therapies (21:21). More On These Topics From The Pink Sheet Price Caps In Regeneron’s COVID Monoclonal Deal With HHS: Not A Precedent, But Enough For Bernie: https://pink.citeline.com/PS148843/Price-Caps-In-Regen...
Scrip’s Five Must-Know Things – 13 September 2023
September 13, 2023 01:53 - 16 minutes - 23.1 MBAudio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities. https://scrip.citeline.com/SC149038/Quick-Listen-Scrips-Five-MustKnow-Things
Trends Shaping The OTC Industry Today, With BSS Consulting’s Birgit Schuhbauer
September 11, 2023 10:21 - 30 minutes - 69.6 MBIn the second part of HBW Insight’s exclusive interview with OTC industry veteran Birgit Schuhbauer, we discuss the trends that will shape the future of consumer health. Drawing on her extensive experience in consumer health, most recently as global vice president of J&J’s Self Care franchise and president of the AESGP,Schuhbauer gives her views on: consumer shifts towards self-care and prevention, digitalisation and e-commerce, supply chain resilience and sustainability. Schuhbauer also give...
지피지기면 백전백승” 대웅이노베이션의 미국시장 전략 (Korean-language podcast)
September 11, 2023 06:53 - 4 minutes - 9.26 MB어동규 대웅이노베이션홀딩스 대표의 Scrip Intelligence 인터뷰 기사를 요약한 내용입니다 https://scrip.citeline.com/SC148741/Know-The-Enemy-And-Know-Yourself-Before-Entering-US-Daewoong-Exec-Advises
Drug Fix: FTC Ends Amgen-Horizon Case, New Ultra-Rare Cancer Partnership, Generic Applications Lag
September 08, 2023 17:17 - 27 minutes - 16.4 MBPink Sheet reporter and editors discuss the US Federal Trade Commission ending its attempt to block the Amgen acquisition of Horizon Therapeutics (:28), a proposed public-private partnership to develop ultra-rare cancer drugs (9:54), and a slow-down in ANDA submissions to the US Food and Drug Administration (22:02). More On These Topics From The Pink Sheet FTC’s Test Case Opposing Amgen-Horizon Deal Ends With No-Bundling Agreement: https://pink.citeline.com/PS148804/FTCs-Test-Case-Opposing-...
Medtech Connect Episode 9: The Intersection Of IVDs And Digital Health
September 07, 2023 17:26 - 14 minutes - 12.9 MBIn this episode, Medtech Insight regulatory reporter Hannah Daniel and managing editor Amanda Maxwell speak to Marcel Gehrung, co-founder and CEO of Cyted. We talk to Marcel about global regulations for Cyted’s product Endosign, and how his company chose to leverage the product’s flexibility to gain approval and reach markets as efficiently as possible. We also talk about different market authorization requirements in the EU, UK, and US, and the use of AI in healthcare spaces in the UK.
Dr Reddy’s MD On The Next Horizon, Owner-Managed Firms, Life Lessons From Birds
September 07, 2023 02:34 - 40 minutes - 23.5 MBDr Reddy's Laboratories' co-chairman and managing director, G V Prasad, talks with Scrip’s Anju Ghangurde about his conversations with late founder Dr Anji Reddy, the company’s “Horizon 2” trajectory, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession issues and his new book. https://scrip.citeline.com/SC149008/Dr-Reddys-MD-On-The-Next-Horizon-OwnerManaged-Firms-Birds-And-Beliefs
Creating A Digital Biotech Story
September 06, 2023 14:21 - 21 minutes - 9.17 MBIn this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.